ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,296.20
-0.32%
S&P ASX All Technology
4,030.80
-1.66%
Brent Oil
73.935
0.00%
US Dollar vs AUD
1.57307
0.00%
Bitcoin
95,525.26
-1.08%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Agenus Inc (AGEN) Share Price

Agenus Inc

Agenus Inc (AGEN)

NASDAQ
3.32
-0.13
(-3.77%)
Closed 24 February 8:00AM
Delayed by 15 minutes
3.36
0.04
(1.20%)
After Hours: 11:59AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.32
Bid
2.95
Offer
3.95
Volume
227,190
3.2701 Day's Range 3.51
2.50 52 Week Range 19.688
Market Cap
77.884M
Previous Close
3.45
Open
3.51
Last Trade
50
@
3.39
Last Trade Time
Financial Volume
US$ 764,799
VWAP
3.3663
Average Volume (3m)
422,592
Shares Outstanding
23,458,929
Dividend Yield
-
PE Ratio
-0.32
Earnings Per Share (EPS)
-10.49
Revenue
156.87M
Net Profit
-245.97M

About Agenus Inc

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multip... Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.agenusbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Agenus Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AGEN. The last closing price for Agenus was US$3.45. Over the last year, Agenus shares have traded in a share price range of US$ 2.50 to US$ 19.688.

Agenus currently has 23,458,929 shares in issue. The market capitalisation of Agenus is US$80.93 million. Agenus has a price to earnings ratio (PE ratio) of -0.32.

Ask ADVFN Intelligence (AI)

AGEN Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
19 February 2025
AGEN (-3.77%)

Form 8-K - Current report
Edgar (US Regulatory)
11 February 2025
AGEN (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 February 2025
AGEN (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
29 January 2025
AGEN (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 January 2025
AGEN (-3.77%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 January 2025
AGEN (-3.77%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1845-5.264659723213.50453.683.332350853.48922385CS
4-0.41-10.99195710463.734.13.093590833.57337816CS
12-0.23-6.478873239443.554.152.584225923.31590014CS
26-1.68-33.656.532.54418823.91988463CS
52-10.086-75.234969416713.40619.6882.5184798110.6495118CS
156-47.08-93.412698412750.467.42.5450595729.56793399CS
260-73.28-95.665796344676.6135.82.5408547846.5753891CS

AGEN - Frequently Asked Questions (FAQ)

What is the current Agenus share price?
The current share price of Agenus is US$ 3.32
How many Agenus shares are in issue?
Agenus has 23,458,929 shares in issue
What is the market cap of Agenus?
The market capitalisation of Agenus is USD 80.93M
What is the 1 year trading range for Agenus share price?
Agenus has traded in the range of US$ 2.50 to US$ 19.688 during the past year
What is the PE ratio of Agenus?
The price to earnings ratio of Agenus is -0.32
What is the cash to sales ratio of Agenus?
The cash to sales ratio of Agenus is 0.5
What is the reporting currency for Agenus?
Agenus reports financial results in USD
What is the latest annual turnover for Agenus?
The latest annual turnover of Agenus is USD 156.87M
What is the latest annual profit for Agenus?
The latest annual profit of Agenus is USD -245.97M
What is the registered address of Agenus?
The registered address for Agenus is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Agenus website address?
The website address for Agenus is www.agenusbio.com
Which industry sector does Agenus operate in?
Agenus operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
BOXLBoxlight Corporation
US$ 3.1099
(51.70%)
1.84M
GDEVGDEV Inc
US$ 20.90
(46.56%)
264.44k
IVVDInvivyd Inc
US$ 1.7501
(44.64%)
37.75M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
DOYUDouYu International Holdings Ltd
US$ 7.19
(-55.31%)
1.28M
MNDRMobile health Network Solutions
US$ 0.5048
(-46.29%)
18.61M
BLUEbluebird bio Inc
US$ 4.09
(-41.90%)
5.44M
GCLGCL Global Holdings Ltd
US$ 3.83
(-31.48%)
635.26k
AXTIAXT Inc
US$ 1.57
(-31.44%)
6.66M
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
ADTXAditxt Inc
US$ 0.0922
(-22.39%)
278.25M
NVDANVIDIA Corporation
US$ 134.43
(-4.05%)
228.15M
HOLOMicroCloud Hologram Inc
US$ 1.565
(31.51%)
190.81M

AGEN Discussion

View Posts
Monksdream Monksdream 2 months ago
AGEN under $3
👍️0
Monksdream Monksdream 4 months ago
AGEN under $5
👍️0
Monksdream Monksdream 6 months ago
AGEN new 52 week low
👍 1
Monksdream Monksdream 7 months ago
AGEN under $7
👍️0
ErnieBilco ErnieBilco 7 months ago
I tossed a couple of coins in the fountain at $7 wishing for 50% or better
👍️0
DP1011 DP1011 7 months ago
Up here. Keep on going!!!
👍️0
jondoeuk jondoeuk 10 months ago
I expect more dilution is on the way after the R/S. Unless they sell non-strategic assets, which is hardly a sustainable business practice.
👍️0
jondoeuk jondoeuk 11 months ago
The co-founder/CEO/Chairman has been for 20+ years pumping the company, telling stories and making promises, all the while getting rich off retail.
👍️ 1
jondoeuk jondoeuk 11 months ago
They are proposing a R/S at a ratio of 1-for-20 https://finance.yahoo.com/news/why-agenus-stock-plummeted-nearly-233805990.html
👍️0
Paullee Paullee 1 year ago
where did you see that ??????
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
ALL OUT...REVERSE SPLIT ANNOUNCEMENT
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
AGEN SMALL GAPPER AND ON TARGET TO 1.04
👍️0
DP1011 DP1011 1 year ago
Interesting, would be nice to see this back over a dollar.
👍️0
Stumblebum Stumblebum 1 year ago
Something is cooking …..last week good upward movement and picked up volume 😊
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
AGEN POPPING HARD TO 1.04
👍️0
axelvento axelvento 1 year ago
A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy

Who knows what does the future hold$$$$$$$
👍️0
Denzel-72 Denzel-72 1 year ago
R/S is coming … money down the drain
👍️0
Monksdream Monksdream 1 year ago
AGEN new 52 week low
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 1 year ago
$AGEN
https://x.com/hannahadad8890/status/1741101133777486197?s=61
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 1 year ago
$AGEN
https://x.com/hannahadad8890/status/1739966219229258048?s=61
👍️0
Doktornolittle Doktornolittle 1 year ago
Admin(s) please erase my post # 1170. I don't think the issues were the fault of B. Riley or ASCO... . Maybe, but it is unclear and not worth having the negativity there for posterity.
👍️0
Monksdream Monksdream 1 year ago
AGEN new 52 week low
👍️0
Monksdream Monksdream 1 year ago
AGEN new 52 week low
👍️0
Monksdream Monksdream 1 year ago
AGEN new 52 week low

👍️0
Monksdream Monksdream 1 year ago
AGEN new 52 week low
👍️0
Doktornolittle Doktornolittle 2 years ago
... B.Riley psswd is in immediate registration confirmation email. That may not be unusual, but the email subject line gives no indication that it contains a psswd. It gives a warm and fuzzy that your registration did go through, so the reader is not compelled to open the email. The reader already knows they registered and the reader does not yet know that they are going to have to login with a password. May be the usual way to do this, but I don't think it is a good way.

As for ASCO GI. Some say the abstracts were embargoed since late-breaking. Maybe so, but why then did the ASCO website instruct me to login to view the abstract. This is with the abstract already located. This is on the abstract page, which only contains the header at that point. Causes confusion.
👍️0
Doktornolittle Doktornolittle 2 years ago
B Riley would not allow me to view the recent webcast. ASCO would not allow me to view the recently "released: Abstracts. No PR from the company. This while Yhoo Finance is so controlled and filtered since the recent takeover that no light escapes there either.

If you had a similar experience, please message me and we can join forces for a complaint to the SEC.

More detail:
B Riley has no contact other than their private email system which does not work.
ASCO: Found the abstracts, but they told me that I had to log in to view the abstract beyond the header and authors. I spent 12 hours trying to do that. After many dead end phone calls and emails, I finally got them to allow me to log in. Went back to the abstract and now they tell me, you don't have access to the abstract. A slightly different message than when I was not logged in, but still no access.

I videotaped my efforts to access the webcast and abstracts. I suggest you do the same if you have problems like this in the future.

These are SEC violations.

Where is the SEC on these things? I suspect they could care less, but I want to find out.
👍️0
Doktornolittle Doktornolittle 2 years ago
SITC Oral Presentation on BOT w/wo BAL tomorrow with about a thousand authors. It is a brief presentation, but there are only 4 such on schedule and they are the last notes of the entire SITC session. It is likely that everybody at SITC who can get to these final presentations will be there. I am no technical expert in these matters, but I am confident that BOT is a big deal for a couple of reasons beyond the data. 1) In a brief presentation after ASCO, there were major league Cancer experts discussing the presented results. Those experts were truly impressed with this activity against cold tumors. I have seen phony looking presentations by small biotech companies, and this was not that. Of that I am certain and will listen to nobody else's opinion about it. 2) Agenus has been touting BOT for years now. They knew from the beginning that they had something very special. For me it is not a great leap of faith to expect big things from BOT w/wo BAL. No posts here in almost a year. None for months at alter forum IV, and alter other forum just went through a huge change. Suddenly no new posts in the last 24 hours in the middle of SITC? I don't thinks so. So far, I give the facelift at hooya a big thumbs down. This is it guys. Your new home.
👍️ 1
stockguard stockguard 3 years ago
AGEN Agenus initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Michael King initiated coverage of Agenus with a Buy rating and $12 price target. The company has developed a broad portfolio of promising antibodies and bispecifics covering many validated targets in immuno-oncology, King tells investors in a research note. The company has "struck multiple lucrative development agreements with some of the industry's leading oncology players," adds the analyst.
👍️0
north40000 north40000 3 years ago
$11 from $12. Buy rating. Analyst has been switching back and forth between $11 and $12. November date on last PT, per GOOGL search.
👍️0
investtemp investtemp 3 years ago
what was the B Riley target price?
👍️0
stockguard stockguard 3 years ago
B. Riley bullish on Novavax, Agenus amid Omicron spread.
B. Riley analyst Mayank Mamtani reiterates his sector-level view of the need for at least annual vaccine boosters and there being a durable COVID vaccine market, sharing many of the attributes with an expanding flu market that has been clearly rewarding differentiated vaccine solutions. The analyst views sustenance of multiple vaccine modalities prevailing over an "mRNA takes all" viewpoint. Mamtani has a Buy rating and a price target of $305 on Novavax (NVAX) as Omicron variant-specific development preparedness and COV-Boost data reiterate robust positioning in global, durable COVID-19, and flu markets. The analyst also has a Buy rating and a price target on Agenus (AGEN) as he believes under-the-radar SaponiQx's adjuvant is poised to play a meaningful role in strong expected protein subunit vaccine demand. He keeps a Neutral rating on Vaxart (VXRT), calling it one of the few "investable" COVID-19 vaccine pipeline programs directly tackling the transmission issue.
👍️0
stockguard stockguard 3 years ago
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
https://finance.yahoo.com/news/agenus-subsidiary-saponiqx-builds-innovative-113000784.html
👍️0
stockguard stockguard 3 years ago
Will not be in the money until it hits their price, no biggie on this small fry:
SEC Form S-3ASR filed by Agenus Inc.
https://quantisnow.com/insight/2002956?s=s



👍️0
pipette pipette 3 years ago
There was an article in Oct 26 did u get that one? Most trading platforms have news with their tickers too.
👍️0
malice1 malice1 3 years ago
China just shut down yahoo and aol. I was on the Yahoo Agen Board. Can anyone keep me updated on any significant news?
👍️0
Jnk Jnk 3 years ago
Got it!
👍️0
stockguard stockguard 3 years ago
Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.
👍️0
Jnk Jnk 3 years ago
Well I just bought a bunch more shares!! Hope it pays out!!
👍️0
stockguard stockguard 3 years ago
UPDATE: Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes
👍️0
stockguard stockguard 3 years ago
Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
https://endpts.com/agenus-calls-out-fda-for-playing-favorites-as-it-pulls-cervical-cancer-bla-at-agencys-request/
👍️0
malice1 malice1 3 years ago
longboarder have any idea what happened the last two days?
👍️0
longboarder7892 longboarder7892 3 years ago
Thank you Dr. Hidalgo for all that you have done here with AGEN in just a few months we went from 2.50 to almost 6.50 and will be helping save lives. I hope your work will do the same for my other company that you are on the board of and the PI of their trial. AGEN is looking great with the BMY investment... mmmm

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Bristol-Myers Squibb Company (NYSE:BMY) and Agenus Inc. (NASDAQ:AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus' proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.
👍️0
conix conix 4 years ago
AGEN Chart

👍️0
ClayTrader ClayTrader 4 years ago
* * $AGEN Video Chart 05-18-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
JohnLocke101 JohnLocke101 4 years ago
Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+
👍️0
iancnyc iancnyc 4 years ago
thank god i heard on
look at that!!!
👍️0
moonurneighbor moonurneighbor 4 years ago
Great news!
👍️0
JohnLocke101 JohnLocke101 4 years ago
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
👍️0
iancnyc iancnyc 4 years ago
what’s going on with this Turd today?
👍️0

Your Recent History

NASDAQ
AGEN
Agenus
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads